Jazz Pharma Plc (JAZZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
Cash Flows From Operating Activities | |||||
Net Income | 414,832 | -224,060 | -329,668 | 238,616 | 523,367 |
Depreciation Amortization | 638,696 | 629,471 | 552,483 | 278,253 | 370,156 |
Income taxes - deferred | -260,217 | -292,251 | 69,198 | -136,937 | -236,610 |
Accounts receivable | -51,883 | -90,135 | -92,735 | -38,647 | -92,326 |
Accounts payable and accrued liabilities | 9,603 | -11,225 | 57,021 | -18,935 | 4,770 |
Other Working Capital | -204,439 | 9,905 | -47,952 | -85,437 | -154,173 |
Other Operating Activity | 545,415 | 1,250,272 | 570,160 | 662,735 | 361,217 |
Operating Cash Flow | $1,092,007 | $1,271,977 | $778,507 | $899,648 | $776,401 |
Cash Flows From Investing Activities | |||||
Change In Deposits | -120,100 | -1,036 | 1,068,181 | -642,675 | 67,900 |
PPE Investments | -23,962 | -29,046 | -27,641 | -15,004 | -25,926 |
Net Acquisitions | N/A | 53,000 | -6,234,792 | 14,259 | -55,074 |
Purchase Sale Intangibles | -19,000 | -469,148 | -17,891 | -364,250 | -142,200 |
Other Investing Activity | -19,000 | -469,148 | -17,891 | -364,250 | -142,200 |
Investing Cash Flow | $-163,062 | $-446,230 | $-5,212,143 | $-1,007,670 | $-155,300 |
Cash Flows From Financing Activities | |||||
Debt Issued | 0 | 0 | 5,191,463 | 1,481,381 | 0 |
Debt Repayment | -31,000 | -582,014 | -1,320,600 | -889,575 | -33,387 |
Common Stock Issued | 46,459 | 98,020 | 135,261 | 99,681 | 57,831 |
Common Stock Repurchased | -269,761 | -54 | 0 | -146,537 | -301,450 |
Other Financing Activity | -50,952 | -45,443 | -35,602 | -16,877 | -16,739 |
Financing Cash Flow | $-305,254 | $-529,491 | $3,970,522 | $528,073 | $-293,745 |
Exchange Rate Effect | 1,137 | -6,222 | -3,207 | 374 | 366 |
Beginning Cash Position | 881,482 | 591,448 | 1,057,769 | 637,344 | 309,622 |
End Cash Position | 1,506,310 | 881,482 | 591,448 | 1,057,769 | 637,344 |
Net Cash Flow | $624,828 | $290,034 | $-466,321 | $420,425 | $327,722 |
Free Cash Flow | |||||
Operating Cash Flow | 1,092,007 | 1,271,977 | 778,507 | 899,648 | 776,401 |
Capital Expenditure | -23,962 | -29,046 | -27,641 | -15,004 | -40,135 |
Free Cash Flow | 1,068,045 | 1,242,931 | 750,866 | 884,644 | 736,266 |